Perspective assessment of COX-1 and COX-2 selectivity of nonsteroidal anti-inflammatory drugs from clinical practice: Use of genetic function approximation

Journal of Chemical Information and Modeling

Volumn 47, Issue 2, 2007, Pages 635-643

  Zambre, Ajit P ^a   Ganure, Ashok L ^b   Shinde, Devanand B ^b   Kulkarni, Vithal M ^a  

^a BHARATI VIDYAPEETH DEEMED UNIVERSITY   (India)

^b DR BABASAHEB AMBEDKAR MARATHWADA UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

APPROXIMATION THEORY; ENZYMES; FUNCTION EVALUATION; GENETIC ENGINEERING; MOLECULAR STRUCTURE; THREE DIMENSIONAL;

ANTI INFLAMMATORY DRUGS; BINDING PROFILES; GENETIC FUNCTION APPROXIMATION; MOLECULAR SHAPE ANALYSIS;

DRUG PRODUCTS;

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR;

ARTICLE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DESIGN; GENETICS; IC 50; METABOLISM; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; DRUG DESIGN; INHIBITORY CONCENTRATION 50; MOLECULAR STRUCTURE; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 34247180081     PISSN: 15499596     EISSN: 1549960X     Source Type: Journal    
DOI: 10.1021/ci6004367     Document Type: Article

References (41)

1. Insel, P. A. Analgesic-Antipyretic and Antiinflammatory Agents and Drugs Employed in the Treatment of Gout. In The Pharmacological Basis of Therapeutics, 9th ed.; Hardman, J., Limbird, L., Molinoff, P., Ruddon, R., Goodman, A., Eds.; McGraw Hill: New York, 1996; pp 617-657.
2. Vane, J. R. Inhibition of Prostaglandin Synthesis as a Mechanism of Action for Aspirin-Like Drugs. Nature New Biol. 1971, 231, 232-235.
3. Marnett, L. J.; Kalgutkar, A. S. Cyclooxygenase 2 Inhibitors: Discovery, Selectivity and the Future. Trends Pharm. Sci. 1999, 20, 465-469.
4. Allison, M. C.; Howatson, A. G.; Torrance, C. J.; Lee, F. D.; Russel, R. I. Gastrointestinal Damage Associated with the Use of Nonsteroidal Antiinflammatory Drugs. New Engl. J. Med. 1992, 327, 749-754.
5. Garell, S.; Matarese, R. A. Renal Effects of Prostaglandins and Clinical Adverse Effects of Non-Steroidal Anti-Inflammatory Agents. Medicine 1984, 63, 165-181.
6. Warner, T. D.; Giulino, F.; Vojnovic, I.; Bukasa, A.; Mitachell, J. A.; Vane, J. R. Nonsteroid Drug Selectivities for Cyclooxygenase-1 Rather Than Cyclooxygenase-2 Are Associated with Human Gastrointestinal Toxicity: A Full in Vitro Analysis. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 7563-7568.
7. Penning, T. D.; Talley, J. J.; Bertenshaw, S. R.; Carter, J. S.; Collins, P. W.; Docter, S.; Graneto, M. J.; Lee, L. F.; Malecha, J. W.; Miyashiro, J. M.; Rogers, R. S.; Regier, D. J.; Yu, S. S.; Anderson, G. D.; Burton, E. G.; Cogburn, J. N.; Gregory, S. A.; Koboldt, C. M.; Perkins, W. E.; Seibert, K.; Veenhuizen, A. W.; Zhang, Y. Y.; Isakson, P. C. Synthesis and Biological Evaluation of the 1,5-Diarylpyrazole Class of Cyclooxygenase-2 Inhibitors: Identification of 4-[5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] Benzene Sulfonamide (SC-58635, Celecoxib). J. Med. Chem. 1997, 40, 1347-1365.
8. Prasit, P.; Wang, Z.; Brideau, C.; Chan, C. C.; Charleson, S.; Cromlish, W.; Ethier, D.; Evans, J. F.; Ford-Hutchinson, A. W.; Gauthier, J. Y.; Gordon, R.; Guay, J.; Gresser, M.; Kargman, S.; Kennedy, B.; Leblanc, Y.; Leger, S.; Mancini, J.; O'Neill, G. P.; Ouellet, M.; Percival, M. D.; Perrier, H.; Riendeau, D.; Rodger, I.; Zamboni, R.; Boyce, S.; Rupniak, N.; Forrest, M.; Visco, D.; Patrick, D. The Discovery of Rofecoxib, [MK 966, Vioxx, 4-(4′-Methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an Orally Active Cyclooxygenase-2-Inhibitor. Bioorg. Med. Chem. Lett. 1999, 9, 1773-1778.
9. Talley, J. J.; Brown, D. L.; Carter, J. S.; Graneto, M. J.; Koboldt, C. M.; Masferrer, J. L.; Perkins, W. E.; Rogers, R. S.; Shaffer, A. F.; Zhang, Y. Y.; Zweifel, B. S.; Seibert, K. 4-[5-Methyl-3-phenylisoxazol-4-yl]- benzenesulfonamide, Valdecoxib: A Potent and Selective Inhibitor of COX-2. J. Med. Chem. 2000, 43, 775-777.
10. Talley, J. J.; Bertenshaw, S. R.; Brown, D. L.; Carter, J. S.; Graneto, M. J.; Kellogg, M. S.; Koboldt, C. M.; Yuan, J.; Zhang, Y. Y.; Seibert, K. N-[[(5-Methyl-3-phenylisoxazol-4-yl)-phenyl] Sulfonyl] Propanamide, Sodium Salt, Parecoxib Sodium: A Potent and Selective Inhibitor of COX-2 for Parenteral Administration. J. Med. Chem. 2000, 43, 1661-1663.
11. Riendeau, D.; Percival, M. D.; Brideau, C.; Charleson, S.; Dube, D.; Ethier, D.; Falgueyret, J. P.; Friesen, R. W.; Gordon, R.; Greig, G.; Guay, J.; Mancini, J.; Ouellet, M.; Wong, E.; Xu, L.; Boyce, S.; Visco, D.; Girard, Y.; Prasit, P.; Zamboni, R.; Rodger, I. W.; Gresser, M.; Ford-Hutchinson, A. W.; Young, R. N.; Chan, C.-C. Etoricoxib (MK-0663): Preclinical Profile and Comparison with Other Agents That Selectively Inhibit Cyclooxygenase-2. J. Pharmacol. Exp. Ther. 2002, 296, 558-566.
12. Solomon, D. H.; Schneeweiss, S.; Glynn, R. N.; Kiyota, Y.; Levin, R.; Mogun, H.; Avorn, J. Relationship between Selective Cyclooxygenase-2 Inhibitors and Acute Myocardial Infarction in Older Adults. Circulation 2004, 109, 2068-2073.
13. Desiraju, G. R.; Gopalakrishnan, B.; Jetti, R. K. R.; Raveendra, D.; Sarma, J. A. R. P.; Subramanya, H. S. Three-Dimensional Quantitative Structural Activity Relationship (3D-QSAR) Studies of Some 1,5-Diarylpyrazoles: Analogue Based Design of Selective Cyclooxygenase-2 Inhibitors. Molecules 2000, 5, 945-955.
14. Chavatte, P.; Yous, S.; Marot, C.; Baurin, N.; Lesieur, D. Three-Dimensional Quantitative Structure-Activity Relationships of Cyclooxygenase-2 (COX-2) Inhibitors: A Comparative Molecular Field Analysis. J. Med. Chem. 2001, 44, 3223-3230.
15. Raichurkar, A. V.; Kulkarni, V. M. 3D-QSAR of Cyclooxygenase-2 Inhibitors by Genetic Function Approximation. Int. Electron. J. Mol. Des. 2003, 2, 242-261.
16. Luong, C.; Miller, A.; Barnett, J.; Chow, J.; Ramesha, C.; Browner, M. F. Flexibility of the NSAID Binding Site in the Structure of Human Cyclooxygenase-2. Nat. Struct. Biol. 1996, 3, 927-933.
17. Gokhale, V. M.; Kulkarni, V. M. Understanding the Antifungal Activity of Terbinafine Analogues Using Quantitative Structure-Activity Relationship (QSAR) Models. Bioorg. Med. Chem. 2000, 8, 2487-2499.
18. Karki, R. G.; Kulkarni, V. M. Three-Dimensional Quantitative Structure Activity Relationship (3D-QSAR) of 3-Aryloxazolidin-2-one Antibacterials. Bioorg. Med. Chem. 2001, 9, 3153-3160.
19. Makhija, M. T.; Kulkarni, V. M. QSAR of HIV-1 Integrase Inhibitors by Genetic Function Approximation Method. Bioorg. Med. Chem. 2002, 10, 1483-1497.
20. Vadlamudi, S. M.; Kulkarni, V. M. 3D-QSAR of Protein Tyrosine Phosphatase 1B Inhibitors by Genetic Function Approximation. Int. Electron. J. Mol. Des. 2004, 3, 586-609.
21. Kharkar, P. S.; Desai, B.; Varu, B.; Loriya, R.; Naliyapara, Y.; Gaveria, H.; Shah, A.; Kulkarni, V. M. Three-Dimensional Quantitative Structure Activity Relationship of 1,4-Dihydropyridines as Antitubercular Agents. J. Med. Chem. 2002, 45, 4858-4867.
22. Rogers, D. G/SPLINES: A Hybrid of Friedman's Multivariate Adaptive Regression Splines (MARS) Algorithm with Holland's Genetic Algorithm. In Proceedings of the Fourth International Conference on Genetic Algorithms, San Diego, CA, 1991; Belew, R. K., Booker, L. B., Eds.; Morgan Kaufmann Publishers Inc.: San Mateo, CA, 1991.
23. Rogers, D.; Hopfinger, A. J. Applications of Genetic Function Approximation to Quantitative Structure-Activity Relationships and Quantitative Structure-Property Relationships. J. Chem. Inf. Comput. Sc. 1994, 34, 854.
24. Cerius2, version 3.5; Molecular Simulations Inc.: San Diego, CA.
25. Venkatarangan, P.; Hopfinger, A. J. Prediction of Ligand-Receptor Binding Thermodynamics by Free Energy Force Field 3D-QSAR Analysis: Application to a Set of Glucose Analogue Inhibitors of Glycogen Phosphorylase. J. Med. Chem. 1999, 42, 2169-2179.
26. Tokarski, J. S.; Hopfiner, A. J. Prediction of Ligand-Receptor Binding Thermodynamics by Free Energy Force Field 3D-QSAR Analysis: Application to a Set of Peptidometic Renin Inhibitors. J. Chem. Inf. Comput. Sc. 1997, 37, 792-811.
27. Hann, M.; Rogers, D. Receptor Surface Models. 2. Application to QSAR Studies. J. Med. Chem. 1995, 38, 2091-2102.
28. Fan, Y.; Shi, L. M.; Kohn, K. W.; Pommier, Y.; Weinstein, J. N. Quantitative Structure-Antitumor Activity Relationship of Camptothecin Analogues: Cluster Analysis and Genetic Algorithm Based Studies. J. Med. Chem. 2001, 44, 3254-3263.
29. Rappe, A. K.; Goddard, W. A., III. Charge Equilibration for Molecular Dynamics Simulations. J. Phy. Chem. 1991, 95, 3358-3363.
30. Hopfinger, A. J. A Quantitative Structure Activity Relationship: Investigation of Dihydrofolate Reductase Inhibition by Baker Triazines Based Upon Molecular Shape Analysis. J. Am. Chem. Soc. 1980, 102, 7196-7206.
31. Waller, C. L.; Opera, T. I.; Giolitti, A.; Marshall, G. R. Three-Dimensional QSAR of Human Immunodeficiency Virus (1) Protease Inhibitors. 1. A CoMFA Study Employing Experimentally Determined Alignment Rules. J. Med. Chem. 1993, 36, 4152-4160.
32. Cramer, R. D., III.; Bunce, J. D.; Patterson, D. E. Cross-Validation, Bootstrapping and Partial Least Squares Compared With Multiple Regressions in Conventional QSAR Studies. Quant. Struct.-Act. Relat. 1988, 7, 18-25.
33. Viswanathan, V. M.; Goshe, A. K.; Revanker, G. R.; Robbins, R. K. Atomic Physicochemical Parameters for Three Dimensional Structure Directed Quantitative Structure - Activity Relationships. 4. Additional Parameters for Hydrophobic and Dispersive Interactions and Their Application for an Automated Superposition of Certain Naturally Occurring Nucleoside Antibiotics. J. Chem. Inf. Comput. Sci. 1989, 29, 163-172.
34. Kurumbail, R. G.; Stevens, A. M.; Gierse, J. K.; McDonald, J. J.; Stegeman, R. A.; Pak, J. Y.; Gildehaus, D. J.; Miayshiro, M.; Penning, T. D.; Seibert, K.; Isakson, P. C.; Stallings, W. C. Structural Basis for Selective Inhibition of Cycooxygenase-2 by Antiinflammatory Agents. Nature 1996, 384, 644-648.
35. Gierse, J. K.; McDonald, J. J.; Hauser, S. D.; Rangwala, S. H.; Koboldt, C. M.; Seibert, K. A Single Amino Acid Difference Between Cyclooxygense-1 (COX-1) and -2 (COX-2) Reverses the Selectivity of COX-2 Specific Inhibitors. J. Biol. Chem. 1996, 271, 15810-15814.
36. Marnett, L. J.; Kalgutkar, A. S. Design of Selective Inhibitors of Cyclooxygenase-2 as Nonulcerogenic Anti-Inflammatory Agents. Curr. Opin. Chem. Biol. 1998, 2, 482-490.
37. Bernard, P.; Charles, T.; Philippe, P.; Jacqueline, B.; Guillaume, De, N. 1,3-Diaryl-4,5,6,7-tetrahydro-2H-isoindole Derivatives. A New Series of Potent and Selective COX-2 Inhibitors in which a Sulfonyl Group Is Not a Structural Requisite. J. Med. Chem. 2000, 43, 4582-4593.
38. Plount Price, M. L.; Jorgensen, W. L. Analysis of Binding Affinities for Celecoxib Analogues with COX-1 and COX-2 from Combined Docking and Monte Carlo Simulations and Insight into the COX-2/COX-1 Selectivity. J. Am. Chem. Soc. 2000, 122, 9455-9466.
39. Llorens, O.; Perez, J. J.; Palomer, A.; Mauleon, D. Structural Basis of The Dynamic Mechanism of Ligand Binding to Cyclooxygenase. Bioorg. Med. Chem. Lett. 1999, 9, 2779-2784.
40. Habbeb, A. G.; Praveen Rao, P. N.; Knaus, E. E. Design and Synthesis of Celecoxib and Rofecoxib Analogues as Selective Cyclooxygenase-2 (COX-2) Inhibitors: Replacement of Sulfonamide and Methanesulfonyl Pharmacophore by an Azido Bioisostere. J. Med. Chem. 2001, 44, 3039-3042.
41. Akaho, E.; Fujikawa, C.; Runion, H. I.; Hill, C. R.; Nakano, H. J. A Study on Binding Modes of Nonsteroidal Anti-Inflammatory Drugs to COX-1 and COX-2 as Obtained by Dock4.0. J. Chem. Software 1999, 5, 1-14.